Literature DB >> 19025986

Novel agents in myeloma: an exciting saga.

Tomer Mark1, Ruben Niesvizky, Morton Coleman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19025986     DOI： 10.1002/cncr.24040

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

1.  Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

Authors:  Andrzej J Jakubowiak; Don M Benson; William Bensinger; David S D Siegel; Todd M Zimmerman; Ann Mohrbacher; Paul G Richardson; Daniel E H Afar; Anil K Singhal; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

Review 2.  Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.

Authors:  Alana L Keller; Daniel W Sherbenou; Peter A Forsberg; Tomer M Mark
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

3.  Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes.

Authors:  Chung-Jen Teng; Han-Tsung Liu; Chun-Yu Liu; Chi-Hsiu Hsih; Jih-Tung Pai; Jyh-Pyng Gau; Jin-Hwang Liu; Tzeon-Jye Chiou; Hui-Chi Hsu; Po-Min Chen; Cheng-Hwai Tzeng; Yuan-Bin Yu
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.